San Mateo, Calif. — January 31, 2022 — RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Karim Karti, former President and CEO of GE Healthcare Imaging, as the company’s Chief Executive Officer (CEO).
“Karim’s tremendous global experience in healthcare technology and digital health makes him an ideal fit for RapidAI. He has a proven track record in driving commercial success, product expansion and global scale. RapidAI is at a very exciting time in our history as we are scaling the company and substantially expanding our product and global footprint. I’m confident Karim will help ensure our continued growth as the worldwide leader in clinical decision making and patient workflow technology,” said Dr. Greg Albers, Chairman and Co-founder of RapidAI. “RapidAI’s unparalleled clinical validation combined with Karim’s thoughtful approach to business growth will ensure that we continue to support hospitals, physicians, and millions of patients as we advance the treatment of neurovascular diseases, as well as other critical medical disorders.”
Karim Karti comes to RapidAI with more than 25 years of experience in the medical technology industry and a demonstrated ability of growing companies and helping them achieve key milestones. He served as Chief Operating Officer at iRhythm Technologies, a cardiac monitoring and AI digital health company. During his tenure, Karim doubled iRhythm’s revenues in 18 months while successfully launching several new breakthrough AI products. Karim also serves as Chairman of the Board for MedTech Acquisition Corporation and is a Director of Rockley Photonics.
Notably, Karim spent over 22 years at General Electric, where he worked as President and CEO of GE Healthcare Korea, before being tapped as President and CEO of Emerging Markets, and subsequently Global Chief Marketing Officer for the entire $20B GE Healthcare division. Karim was appointed President and CEO of GE Healthcare Imaging in 2016 and led it to become one of the fastest growing businesses at GE in 2017. In this position, Karim drove significant growth, profitability, and innovation, spearheading a new digital platform and investments in AI-based imaging.
“I am proud and humbled to join Dr. Albers, Dr. Roland Bammer, and the whole team at RapidAI in their mission to improve the diagnosis and treatment of life-threatening conditions. As trailblazers in the space, RapidAI has helped to shape the way we diagnose and treat neurovascular and vascular disease and made a meaningful impact in the lives of people around the world,” said Karti. “I look forward to bringing my own experience in imaging, artificial intelligence and digital health to help push the boundaries of clinical technology and patient care even further and continue to save lives. RapidAI has pioneered the field with five key randomized clinical trials, all published in the New England Journal of Medicine, that set a new standard for stroke treatment worldwide and showed the superior approach of the RapidAI solution. RapidAI is the undisputed leader with a presence in over 2000 hospitals and 60 countries, a testament to the value of RapidAI for patients, physicians, hospitals and health systems.”
Karim’s leadership philosophy is rooted in open communication and nurturing talent and diversity. He believes in a leadership approach that combines full transparency, teamwork and collaboration with a passion for advancing clinical innovation and helping patients around the world. Karim has a MSc in engineering from Ecole Centrale de Lyon and completed the entrepreneurship program of Ecole Superieure de Commerce de Lyon. He lives with his wife and two daughters in the Bay Area.
"I have been extremely impressed by the depth of Karim’s experience, leadership and passion for innovation. I look forward to working with him as we expand the breadth and depth of our product portfolio," said Dr. Roland Bammer, CTO and Co-founder of RapidAI.
RapidAI’s platform leverages AI to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, which are available to physicians through PACS, email, and the Rapid mobile and web apps. The technology helps physicians make expedient diagnoses, treatment and transfer decisions, and allows for more streamlined communication and coordination of the patient journey. Though its foundations are in the treatment of stroke, RapidAI technology has evolved to cover aneurysm and pulmonary embolism, with continued advancements to come. RapidAI has processed more than 4 million scans on its platform – the most clinically advanced in the industry.